SAN FRANCISCO, Jan 13 (Reuters) - AstraZeneca has agreed to buy Boston-based Modella AI, the companies said on Tuesday, as the drug industry increases its use of artificial intelligence to accelerate the discovery of new drugs.
The companies did not disclose financial terms. In a press release, Modella AI said its "foundation models" and AI agents would be integrated into oncology research and development to support clinical development and biomarker discovery.
"Oncology drug development is becoming more complex, more data-rich and more time-sensitive," said Gabi Raia, Modella AI's chief commercial officer, adding that joining AstraZeneca would allow it to deploy its tools in global trials and clinical settings.
AstraZeneca said that this was the first acquisition of an AI firm by a big pharmaceutical company.
In an interview at the JP Morgan Healthcare Conference, AstraZeneca Chief Financial Officer Aradhana Sarin said the acquisition would "supercharge" the company's quantitative pathology and biomarker discovery efforts by bringing more data and AI capabilities in-house.
The deal was one of a number of pacts between major drug firms and AI companies that were unveiled at the healthcare conference, including a $1 billion collaboration between Nvidia and Eli Lilly. They plan to build a new research lab using Nvidia's latest-generation AI chips.
Modella will accelerate AstraZeneca’s efforts to make pathology more quantitative - using computers to analyze biopsies for relevant proteins and correlate them with clinical data - so AstraZeneca can develop “highly targeted biomarkers and then highly targeted therapeutics,” Sarin said.
The deal is an expansion of a multi-year collaboration that the companies unveiled in July.
Sarin said that partnership served as a "test drive," adding that AstraZeneca ultimately wanted Modella's data, foundation models and AI talent in-house.
She said AI tools could be used to more rapidly select patients for drug trials, which could increase the odds of clinical success and cut related costs.
(Reporting by Maggie Fick; Editing by Thomas Derpinghaus)
LATEST POSTS
- 1
Turkey key underlying issue as Israel, Greece, Cyprus hold summit - 2This professional Santa's dream of spreading holiday cheer fuels stroke recovery
- 3German mid-sized firms gloomy on outlook, survey finds
- 4Are protests pushing Iran's Islamic regime toward a tipping point?
- 5Analysis-NASA's moon mission tests aerospace old guard as SpaceX, Blue Origin hover
- Foods with healthy-sounding buzzwords could be hiding added sugar in plain sight
- It Shouldn’t Be Here: Rescuers Race to Save Whale Stranded in Rare Spot
- Brazil Passes Law to Use Seized Bitcoin, Crypto to Fund Public Security Measures
- ONE returns to Red Sea with new service
- Joshua Made Last-Second Seat Change That Saved His Life
- Paraplegic engineer becomes the first wheelchair user to blast into space
- Exploring the School Application Cycle: Understudy Bits of knowledge
- The most effective method to Comprehend the Variables Affecting Medical attendant Pay rates
- Two die and thousands homeless after flooding hits Russia's Dagestan
